The FDA peptide panel explained: both meetings and what each vote means
Reviewed 14 sourcesPublished by PepVault
FDA's compounding panel voted for six peptides in July 2026, against FDA's own proposals. What that changed, and what GHK-Cu, melanotan II and LL-37 face next.

- Last reviewed
- Sources
- 14
- Questions
- 8
- Compounds
- 12
The short answer
The FDA's Pharmacy Compounding Advisory Committee advises whether pharmacies may compound a peptide from raw powder; FDA decides. In July 2026 it backed six, BPC-157 among them, against FDA's proposals, and HHS now tolerates compounding those six. Its next meeting, before the end of February 2027, takes GHK-Cu (FDA tolerates compounding it today, except as an injection), melanotan II, LL-37, dihexa and PEG-MGF (no 503A route today).
Evidence: Primary documents only: FDA's meeting pages, briefing and category lists, the Code of Federal Regulations, the Federal Register and HHS's policy text. Vote counts are not in any of them.

What is the FDA peptide panel?
It is the Pharmacy Compounding Advisory Committee, or PCAC: a standing FDA committee of at least 10 voting members, chosen from pharmacy compounding, medicine and related fields, that advises the FDA Commissioner on compounded drugs12. The law requires FDA to consult it before it adds a substance to the list pharmacies may compound from10.
Its vote is advice, and FDA said so in its own July 2026 briefing: it brings issues to the committee "to obtain the advisory committee's advice" and makes no final determination until that input and all its reviews are in2. A peptide reaches the list only through notice-and-comment rulemaking: a proposed rule, public comments, then a final rule7.
The most striking fact of 2026 is that the two sides disagreed. FDA proposed that every peptide at the July meeting "NOT be included"2, and the committee voted in favour of six of them anyway, as HHS's own policy records10.
This guide explains public FDA and HHS documents as they stood on November 20, 2026. It is a legal explainer, not legal advice.

What is a 503A compounding pharmacy?
Compounding means a licensed pharmacist or physician mixing or altering ingredients to make a medicine for one patient9. Section 503A of the federal drug law covers state-licensed pharmacies, federal facilities and licensed physicians, and it requires a valid prescription for an individual patient10. State boards of pharmacy oversee these pharmacies day to day11. Outsourcing facilities fall under a separate section, 503B, and FDA oversees them directly11.
A compounded drug is not FDA-approved: FDA does not check its safety, effectiveness or quality before it is sold11. Under 503A, a pharmacy may compound from a raw powder (a bulk drug substance) only if the substance has a USP or NF quality monograph, is part of an FDA-approved drug, or is on FDA's 503A bulks list2.
That list is short. Since 2019 it has held six substances, five of them for use on the skin only, and no peptide8. So for a peptide with no approved drug and no monograph, the bulks list decides whether a pharmacy can make it.
What do FDA's categories 1, 2 and 3 mean?
While FDA works through the nominations, it sorts each substance into one of three categories, and the category decides what FDA does in the meantime7.
| Category | What it means | What FDA does meanwhile | Peptides in it (May 14, 2026) |
|---|---|---|---|
| 1: under evaluation | Nominated with enough information to evaluate | Does not intend to act against a pharmacy that meets its interim conditions | GHK-Cu (except injectable routes), vasoactive intestinal peptide |
| 2: significant safety risks | Nominated, evaluated, and FDA found significant safety risks | No category 1 protection; general enforcement applies | Kisspeptin-10 |
| 3: without adequate support | Nominated without enough information to evaluate | No category 1 protection; can be nominated again | Mechano growth factor (MGF), GHRP-2, GHRP-6, cibinetide (ARA-290), thymulin acetate |
| Nominated but withdrawn | The nominator withdrew it; FDA's safety page still lists its risks | No category 1 protection; general enforcement applies | BPC-157, TB-500, melanotan II, LL-37, dihexa, PEG-MGF and others |
Sources:567. A peptide in no category is not on a path to compounding until FDA takes it up again, which is what both panels do: FDA chose to present the July peptides even though their nominators had withdrawn them2.
What happened at the first meeting, July 23–24, 2026?
FDA put seven peptides to the committee, each for the medical uses named in its nomination, and asked one question per form: should it be placed on the list13? For every one, FDA's answer was no2.
| Peptide | Uses FDA reviewed | FDA proposed | Committee | HHS policy since Oct 30 |
|---|---|---|---|---|
| BPC-157 | Ulcerative colitis | Not to include | Voted in favour | Acetate: under the skin, into muscle, oral, topical |
| KPV | Wound healing, inflammatory conditions | Not to include | Voted in favour | Acetate: topical, oral |
| TB-500 | Wound healing | Not to include | Voted in favour of both forms | Acetate: under the skin, into muscle |
| MOTS-c | Obesity, osteoporosis | Not to include | Voted in favour of both forms | Acetate: under the skin, into muscle |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Not to include | Voted in favour of both forms | Free base: in the nose |
| Epitalon | Insomnia | Not to include | Voted in favour | Acetate: under the skin, into muscle, in intermittent courses |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | Not to include | Not recorded by FDA or HHS | Not covered |
The uses and proposals come from FDA's meeting page and briefing12; the votes and routes from the appendix of HHS's policy10. FDA's meeting page, current as of August 6, 2026, lists no minutes, transcript or voting results, and HHS's policy records only which way the committee voted. Vote counts reported in the press have no FDA or HHS document behind them110.
What did HHS decide on October 30, 2026?
HHS published an enforcement discretion policy in the Federal Register (91 FR 68526, RIN 0910-ZD94)9. Enforcement discretion means the agency says it does not intend to act against something it could act against. Until a final rule decides each peptide, HHS does not intend to act against a 503A pharmacy, federal facility or physician compounding the six peptides in its Appendix A: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-50010.
HHS gave its reasons in the policy: newer certificates of analysis from FDA-registered manufacturers, documented use, the committee's votes, and a goal of moving people away from research-use-only peptides made abroad10. Its conditions, in short:
- A prescription for an individual patient, as 503A already requires.
- Only the forms and routes named in Appendix B (the last column of the table above).
- Powder from an FDA-registered manufacturer, with a certificate of analysis covering identity, purity, endotoxins, microbes and impurities.
- One active ingredient per product, labelled "This is a compounded drug product. Not for resale."
- Serious adverse events and quality problems reported to FDA's MedWatch and to the states.
- Only an FDA-cleared syringe as the device; an oral form needs records that it is absorbed in people.
It is not an approval and not a rule. The Federal Register notice calls it a draft policy, says it binds neither HHS nor the public, and lets HHS revisit it if a safety signal or quality problem appears9. Comments ran for two weeks, to November 13, 202613.
Which peptides are on the second meeting's list?
FDA's notice names five, each "being considered for inclusion on the 503A bulks list": cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF)4. It names no medical uses yet and no date beyond "before the end of February 2027"4.
| Peptide | Where FDA has it today | What FDA's safety page says | A yes could lead to | A no could lead to |
|---|---|---|---|---|
| GHK-Cu | Category 1 for routes other than injection; injectable form nominated but withdrawn56 | Limited human safety data; injected forms may carry an immune-reaction risk | FDA may propose a rule adding it, possibly route by route | FDA may propose leaving it off; FDA has not said which routes it will review |
| Melanotan II | Nominated but withdrawn; in no category6 | Case reports of melanoma, a brain-swelling syndrome and priapism | A proposed rule that could add it | No change until FDA rules |
| LL-37 | Nominated but withdrawn; in no category6 | Effects on male reproduction in nonclinical (lab and animal) studies; FDA also notes it may promote tumours in some tissues | A proposed rule that could add it | No change until FDA rules |
| Dihexa | Nominated but withdrawn; in no category6 | No human exposure data found | A proposed rule that could add it | No change until FDA rules |
| PEG-MGF | Nominated but withdrawn; plain MGF is in category 356 | No human exposure data found | A proposed rule that could add it | No change until FDA rules |
None of the five has an FDA-approved product, so the bulks list is the only 503A route for any of them. Our legal-status pages for GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF carry the full FDA, DEA and sport status of each.
What would a yes or a no change for someone using these peptides?
On the day of the vote, nothing changes in law. A vote goes to FDA, and the list changes only with a final rule after a proposed rule and public comments7. A "no" that FDA adopts looks like 2019, when its final rule named four substances that "will not be included", piracetam among them8.
The July meeting shows the faster path. About three months after the committee voted for six peptides, HHS used enforcement discretion to cover them while rulemaking goes on10. Whether it does the same after February is HHS's choice; nothing obliges it.
Three things no vote changes. A compounded peptide is still not an FDA-approved drug11. A prescription for one patient is still the 503A requirement10. And the status in sport is set by WADA, not FDA.
PepVault keeps every dose you log, with its compound and date, and turns that record into a doctor's report, so the prescriber who decides on a compounded peptide sees exactly what you take. Log it in PepVault
When will we know?
Before the July meeting, FDA published a meeting notice with a public docket in the Federal Register on April 16, 202614, then posted its briefing and questions1. For the second meeting, FDA says it will publish such a notice; as of November 20, 2026 the Federal Register held none, and FDA's page still read "before the end of February 2027"4.
- Watch for the Federal Register notice: it sets the date and opens the comment docket4.
- Read FDA's briefing for each peptide: its proposal ("include" or "NOT be included") and the uses it reviewed.
- After the meeting, look for the votes on FDA's page or in a later HHS or FDA document.
- Then watch for a proposed rule, or a new HHS policy like October's.
As of November 20, 2026, the second meeting has not been held. When it is, this guide adds FDA's proposal and the committee's vote for each of the five.
Sources
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026). fda.gov
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026. fda.gov
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Questions. fda.gov
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027; content current as of April 15, 2026). fda.gov
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026). fda.gov
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). fda.gov
- 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, up to date as of November 18, 2026). ecfr.gov
- Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026 (FR Doc. 2026-22192). federalregister.gov
- Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 2026). hhs.gov
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (content current as of September 16, 2025). fda.gov
- U.S. Food and Drug Administration. Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal. Federal Register 91 FR 23275, April 30, 2026 (FR Doc. 2026-08378). federalregister.gov
- Regulations.gov. Docket HHS-OASH-2026-0496: HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. regulations.gov
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Federal Register 91 FR 20465, April 16, 2026 (FR Doc. 2026-07361). federalregister.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.